Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine

Sponsor
Children's Hospital of Fudan University (Other)
Overall Status
Recruiting
CT.gov ID
NCT03963752
Collaborator
(none)
164
1
2
28.6
5.7

Study Details

Study Description

Brief Summary

Our study used a randomized controlled trial to validate the clinical efficacy of a combination of traditional Chinese and Western medicine in the treatment of children with rapid progressive central precocious puberty.

Condition or Disease Intervention/Treatment Phase
  • Drug: Ziyinxiehuo Granules Herbs
  • Drug: Megestrol Acetate Tablet
  • Drug: Leuprorelin Acetate 3.75mg Injection
Phase 4

Detailed Description

In the research, 164 subjects diagnosed with rapid progressive idiopathic precocious puberty are randomly divided into Group Ziyinxiehuo Granules and Megestrol Acetate Tablet(82 cases)and Group Gonadotrophin ( 82 cases). Patients in Group Ziyinxiehuo Granules and Megestrol Acetate Tablet are treated with ziyinxiehuo Granules and megestrol acetate tablet , whereas the Group Gonadotrophin received with gonadotrophin releasing hormone agonist, and all the subjects in two groups are continuously treated for 6 months.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
164 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evidence-based Medical Research on the Treatment of Children's Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine
Actual Study Start Date :
Aug 15, 2019
Anticipated Primary Completion Date :
Dec 31, 2021
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Ziyinxiehuo Granules and Megestrol Acetate

Experimental:Group Ziyinxiehuo Granules and Megestrol Acetate Tablet Intervention :Subjects in Group Ziyinxiehuo Granules and megestrol acetate tablet will be treated with Ziyinxiehuo Granules and megestrol acetate tablet for 6 months.1 pack of Ziyinxiehuo granules Herbs includes shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g. Ziyinxiehuo Granules is administered after dissolved,1pack every time, 2 times per day after a meal; and the dosage of megestrol acetate is 6-8mg/d, which is taken in 3 times after a meal.

Drug: Ziyinxiehuo Granules Herbs
1 pack of Ziyinxiehuo granules Herbs is administered after dissolved, 2 times per day after a meal.
Other Names:
  • nourishing"Yin"-removing"Fire" Granules
  • Drug: Megestrol Acetate Tablet
    the dose is 6-8mg/d, three times per day after meals.

    Active Comparator: Gonadotrophin

    Active Comparator: Group Gonadotrophin Intervention: Subjects in Group Gonadotrophin will be treated with gonadotrophin releasing hormone agonist for 6months. In our study Leuprorelin Acetate 3.75mg Injection will be applied, the dosage of which is 80μg/kg every time by subcutaneous injection, every 4 weeks for once.

    Drug: Leuprorelin Acetate 3.75mg Injection
    Usage: 80μg/kg by subcutaneous injection, every 4 weeks

    Outcome Measures

    Primary Outcome Measures

    1. Percentage of the Mammary Nucleus Diameter reduced to less than 1cm [After six months of continuous treatment]

      The investigators will measure subjects' mammary nucleus diameter through the midline of the breast with a ruler after six months of continuous treatment, and percentage of the mammary nucleus diameter reduced to less than 1cm in each group will be calculated.

    Secondary Outcome Measures

    1. Ratio of bone age difference to chronological age difference [After six months of continuous treatment]

      The left hand orthotopic X-ray (including the carpal bone and the lower end of the ulna) will be filmed by the Department of Radiology before and after treatment, and the bone age will be measured according to the Greulich-Pyle map method. Ratio of bone age difference to chronological age difference will be calculated.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    5 Years to 8 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Girls are diagnosed as Idiopathic central precocious puberty by GnRH (gonadotrophin releasing hormone)Stimulation Test, and their age of onset ≤8 years;

    • Tanner stages of breast in female patients ≥ Tanner III stage,diameter of mammillary nucleus ≥ 3cm;

    • B-type ultrasonography: the volume of uterus≥3ml, the volume of ovary≥1.5ml, the diameter of follicle≥4mm;

    • Bone age: compared the chronological age, the bone age is more than 1 year and the bone age <11.5 years old;

    • It progresses rapidly, ratio of bone age difference to chronological age difference> 1;

    • No GnRH analogs or sex hormones were administrated in the past;

    • All above are needed at the same time.

    Exclusion Criteria:
    • Precocious precocity caused by the central nervous system organic diseases;

    • Precocious precocity caused by congenital hypothyroidism, congenital adrenal hyperplasia, adrenal tumor and ovarian or testicular neoplasms as well as McCune-Albright syndrome, etc;

    • Precocious precocity with a family history of diseases such as tumor, leukemia, diabetes, systemic lupus erythematous;

    • Pseudo sexual precocity and partial precocious puberty.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Children's Hospital of Fudan University Shanghai Shanghai China 201102

    Sponsors and Collaborators

    • Children's Hospital of Fudan University

    Investigators

    • Study Chair: Jian Yu, professor, Children's Hospital of Fudan University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jian Yu, Director of TCM Department, Children's Hospital of Fudan University
    ClinicalTrials.gov Identifier:
    NCT03963752
    Other Study ID Numbers:
    • 18401902300
    First Posted:
    May 28, 2019
    Last Update Posted:
    Jul 29, 2021
    Last Verified:
    Jul 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Jian Yu, Director of TCM Department, Children's Hospital of Fudan University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 29, 2021